How can the genetic therapy create drugs for rare diseases UK news

A new study says that the new portable genetic therapy can allow hospital pharmacies to create dedicated medications upon request.

Rare diseases affect more than 300 million people worldwide – 36 million in the European Union alone – but are often ignored due to the patient’s numbers and high costs in developing medicines.

Most medications are manufactured in factories and shipped to hospitals, but for rare cases often there are not enough patients for companies to justify the development of drugs in large quantities.

However, the NANOSPRESSO project can allow pharmacists to create medicines for them upon request, according to a paper published in the border in science.

The pharmacist who uses the device puts the ingredients (such as genetic materials and fats) in a small cartridge, then mixes the device together in a very accurate way. Then the targeted small drug in the patient can be injected.

Professor Raymond Shevlors, who led the project, said there is an “urgent need” to create specialized drugs in hospitals and on demand in a reasonable way.

“By converting production to the care point, nanospresso can help bring the changing micro -medications for patients.”

However, Nanospresso faces great obstacles before being seen in preparing health care any time soon.

The medications that create them will need to meet strict safety and quality standards, and the organizers will need to determine how to agree and monitor individual treatments.

“Nansbriso can create how we deal with rare diseases by bringing personal medicine to more patients, faster,” says the author of the study, Dr. Mariona Estabi Centi.

“The device can be easy to use at reasonable prices allowing paramedics to deal with conditions that cannot be managed by traditional methods.”

The study indicates a historical precedent for pharmacies that produce medicines – until the twentieth century, routinely pharmacists have prepared hand -designed drugs.

They also cite the success of the use of DNA platforms similar to the production of flexible vaccines during the Covid-19s, and they say that modern developments in the microcredit in the closed system have enabled such breaches.